Urologic Diseases
123
25
29
54
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
14 trials with published results (11%)
Research Maturity
54 completed trials (44% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.1%
10 terminated out of 123 trials
84.4%
-2.1% vs benchmark
11%
13 trials in Phase 3/4
26%
14 of 54 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 54 completed trials
Clinical Trials (123)
Developing a PROM for Recurrent Urinary Tract Infection
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures
Effect of Comprehensive Spa Care on Kidney and Urological Conditions: A Clinical Study in Adult Patients
Trial for Reliability of Urodynamics SysTem
Brain Activity Among Children With Overactive Bladder and Daytime Urinary Incontinence and Healthy Children
The Voided Urinary, Perineal, and Faecal Microbiota Among Children and Adolescents - the PpUF-study.
Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora
Evaluation Patient Satisfaction After Passive Bladder Catheter Removal Compared to Active Removal
INTIBIA Pivotal Study
A Study of Ward Admissions for Haematuria
Registry for Patients Undergoing AUS Surgery for Female SUI Due to ISD
Active Informed Consent: a New Solution to Improve and Objectively Test the Patient Understanding of Complex Surgical Procedures Proposals
Evaluation of AI Large Models for Diagnosis and Treatment in Real-World Cases: Multicenter Retrospective Study
Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient Outcomes
VIrtual Reality Induced Pain and anxiEty Relief in Outpatient UROlogical Procedures
Bovine Colostrum for Prophylaxis Against Recurrent Urinary Tract Infection in Children
Modern Urodynamics System Efficacy (MUSE) Study
Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)